Evidence map›Paper›PMID 18495848›Full record

Trial reportClinical and vaccine immunology : CVI2008

Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique.

Diana Quelhas, Laura Puyol, Llorenç Quintó, Elisa Serra-Casas, Tacilta Nhampossa, Eusebio Macete, Pedro Aide, Alfredo Mayor, Inacio Mandomando, Sergi Sanz and 6 more

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Diana QuelhasCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Laura Puyol
Llorenç Quintó
Elisa Serra-Casas
Tacilta Nhampossa
Eusebio Macete
Pedro Aide
Alfredo Mayor
Inacio Mandomando
Sergi Sanz
John J Aponte
Virander S Chauhan
Chetan E Chitnis
Pedro L Alonso
Clara Menéndez
Carlota Dobaño
Instituto Nacional de Saúde · MZManhiça Health Research Centre · MZConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInternational Centre for Genetic Engineering and Biotechnology · INUniversitat de Barcelona · ESMinistry of Health · MZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the impact of intermittent preventive treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP), which was given at ages 3, 4, and 9 months through the Expanded Program on Immunization (EPI), on the development of antibody responses to Plasmodium falciparum in Mozambique. Immunoglobulin M (IgM) and IgG subclass antibodies specific to whole asexual parasites and to recombinant MSP-1(19), AMA-1, and EBA-175 were measured at ages 5, 9, 12, and 24 months for 302 children by immunofluorescence antibody tests and by enzyme-linked immunosorbent assays. Antibody responses did not significantly differ between children receiving IPTi with SP and those receiving a placebo at any time point measured, with the exception of the responses of IgG and IgG1 to AMA-1 and/or MSP-1(19), which were significantly higher in the SP-treated group than in the placebo group at ages 5, 9, and/or 24 months. IPTi with SP given through the EPI reduces the frequency of malarial illness while allowing the development of naturally acquired antibody responses to P. falciparum antigens.

Indexed as

AntimalarialsPyrimethamineSulfadoxineAnimalsAntibodies, ProtozoanAntigens, ProtozoanChild, PreschoolDrug Administration ScheduleDrug CombinationsErythrocytesHumansImmunoglobulin GImmunoglobulin MInfantMalaria, FalciparumMozambiqueAntibodies, ProtozoanAntigens, ProtozoanAntimalarialsDrug Combinationsfanasil, pyrimethamine drug combinationImmunoglobulin GImmunoglobulin MPyrimethamineRecombinant ProteinsSulfadoxine

Identifiers

PMID18495848
PMCPMC2519318
OpenAlexW2137642662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.